Adherex Technologies Share Price - AHX, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(TSE:AHX, AHX.TO)

Adherex Technologies
adherex.com

Adherex Technologies Inc. (Adherex) is a biopharmaceutical company focused on cancer therapeutics. The Company has two products in the clinical stage of development, including Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, which improves the tolerability and effectiveness of 5-fluorouracil (5-FU) and STS is a chemoprotectant being developed to reduce or prevent hearing loss that may result from treatment with platinum-based chemotherapy drugs

News

07/10/11
Adherex to meet with FDA Subcommittee on STS treatment

All Adherex Technologies News ►

Recent Sector News

Dow higher on home sales data, Dell earnings in focus

U.S. equity markets moved higher Tuesday afternoon as investors welcomed a report showing existing home sales surged in April for the first time since January.
Dow points to red on Japan downgrade, Apple, Facebook in focus

U.S. equity markets looked set to open lower Tuesday after Fitch Ratings cut Japan’s credit rating, citing rising public debt and slow deficit-reduction efforts.
Q1 gold demand underpinned by China, Central Banks and ETFs

Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up

Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
Facebook boosts public offering by 25%

Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
Snipp plans ambitious growth as mobile marketing takes off

Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.